Multipotent adult progenitor cells prevent functional impairment and improve development in inflammation driven detriment of preterm ovine lungs

Sophie M.L. Neuen,Daan R.M.G. Ophelders,Helene Widowski,Matthias C. Hütten,Tim Brokken,Charlotte van Gorp,Peter G.J. Nikkels,Carmen A.H. Severens-Rijvers,Mireille M.J.P.E. Sthijns,Clemens A. van Blitterswijk,Freddy J. Troost,Vanessa L.S. LaPointe,Shahab Jolani,Christof Seiler,J. Jane Pillow,Tammo Delhaas,Niki L. Reynaert,Tim G.A.M. Wolfs

DOI: https://doi.org/10.1016/j.reth.2024.03.014

IF: 3.651

2024-03-31

Regenerative Therapy

Abstract:Highlights • Prenatal inflammation sensitizes the immature lung to postnatal inflammatory stress. • Perinatal lung inflammation hinders development and function of the immature lung. • MAPC therapy regenerates structure of the immature lung following inflammation. • MAPC therapy restores function of the inflamed preterm lung. • MAPC therapy induces maturation in the developing alveoli. Background Perinatal inflammation increases the risk for bronchopulmonary dysplasia in preterm neonates, but the underlying pathophysiological mechanisms remain largely unknown. Given their anti-inflammatory and regenerative capacity, multipotent adult progenitor cells (MAPC) are a promising cell-based therapy to prevent and/or treat the negative pulmonary consequences of perinatal inflammation in the preterm neonate. Therefore, the pathophysiology underlying adverse preterm lung outcomes following perinatal inflammation and pulmonary benefits of MAPC treatment at the interface of prenatal inflammatory and postnatal ventilation exposures were elucidated. Methods Instrumented ovine fetuses were exposed to intra-amniotic lipopolysaccharide (LPS 5 mg) at 125 days gestation to induce adverse systemic and peripheral organ outcomes. MAPC (10 × 10 6 cells) or saline were administered intravenously two days post LPS exposure. Fetuses were delivered preterm five days post MAPC treatment and either killed humanely immediately or mechanically ventilated for 72 h. Results Antenatal LPS exposure resulted in inflammation and decreased alveolar maturation in the preterm lung. Additionally, LPS-exposed ventilated lambs showed continued pulmonary inflammation and cell junction loss accompanied by pulmonary edema, ultimately resulting in higher oxygen demand. MAPC therapy modulated lung inflammation, prevented loss of epithelial and endothelial barriers and improved lung maturation in utero . These MAPC-driven improvements remained evident postnatally, and prevented concomitant pulmonary edema and functional loss. Conclusion In conclusion, prenatal inflammation sensitizes the underdeveloped preterm lung to subsequent postnatal inflammation, resulting in injury, disturbed development and functional impairment. MAPC therapy partially prevents these changes and is therefore a promising approach for preterm infants to prevent adverse pulmonary outcomes.

engineering, biomedical,cell & tissue engineering